Dupixent is used to treat certain cases of: Dupixent comes as a single-dose prefilled syringe and a single-dose prefilled pen. You may receive your Dupixent injections at your doctor’s office.

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Dupixent comes in a prefilled syringe or prefilled pen for injection under the skin. Dupixent is used to treat the following in certain situations: Dupixent contains the active ingredient dupilumab.

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous urticaria, significantly reducing symptoms like itch and ...